Oncolytics said it had updates and progress on its REO 033 colorectal cancer study. The excerpt gives no study findings or patient outcomes, so it does not show a change in the company's outlook.
The filing excerpt does not say what changed in the study or report patient outcomes. The mention of progress sounds encouraging, but without details, it does not show whether the treatment is helping.
Follow Oncolytics Biotech Inc. (ONCY) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ONCY